#SFHS2609111AOrder of April 10, 2026, Modifying the List of Reimbursable Pharmaceutical Specialties for Social Insurance Beneficiaries
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law adds three specific medications to the list of drugs that can be reimbursed by social insurance in France. These medications are intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Healthcare providers and pharmacies should update their formularies to include these medications.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds three ADHD medications for children and adolescents to the reimbursable drug list.
- Specifies reimbursement is only for ADHD when other measures are insufficient.
- Medications are chewable, extended-release tablets with different dosages.
Obligations
What this law requires
Add TUZULBY 20 mg, 30 mg, and 40 mg (methylphenidate hydrochloride) to the list of reimbursable pharmaceutical specialties
Ensure reimbursement of the three TUZULBY medications is limited exclusively to treatment of ADHD (Attention Deficit Hyperactivity Disorder) in children and adolescents aged 6-17 years
Only reimburse TUZULBY for ADHD when corrective measures alone have proven insufficient
Update formularies to include TUZULBY 20 mg, 30 mg, and 40 mg chewable tablets in extended-release format (bottles of 28 tablets)
Implement the reimbursement modifications effective on the fourth day following publication in the Journal officiel de la République française